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Abstract
Background: Recently published randomized controlled trials have shown different results compared to the
Fraction Flow Reserve Versus Angiography for Multi-vessel Evaluation (FAME) study. Therefore, this current analysis
aimed to compare the adverse clinical outcomes associated with Fraction Flow Reserve (FFR)-guided versus
standard angiography-guided Percutaneous Coronary Intervention (PCI) using a large number of randomized
patients.
Methods: PubMed/Medline, EMBASE and the Cochrane library were searched for studies comparing FFR-guided
with angiography-guided PCI. Mortality, Myocardial Infarction (MI), repeated revascularization and Major Adverse
Cardiac Events (MACEs) at any follow up period following PCI were considered as the clinical endpoints in this
analysis. Odds Ratios (OR) with 95% Confidence Intervals (CIs) were calculated and the analyses were carried out by
the RevMan 5.3 software. Ethical approval was not necessary for this type of study.
Results: A total number of 2138 patients (1080 patients with FFR-guided versus 1058 patients with angiography-
guided PCI) were included. Results of this analysis showed mortality not to be significantly different between FFR-
guided and angiography-guided PCI with OR: 0.70, 95% CI: 0.39 – 1.25; P = 0.22, I2 = 0%. Total repeated
revascularization and Target Lesion Revascularization were also similarly manifested with OR: 0.82, 95% CI: 0.60 – 1.
13; P = 0.22, I2 = 0% and OR: 0.88, 95% CI: 0.43 – 1.80; P = 0.73, I2 = 0% respectively. In addition, MACEs were also not
significantly lower in the FFR-guided PCI group with OR: 0.82, 95% CI: 0.64 – 1.06; P = 0.13, I2 = 0%. However, FFR-
guided PCI was associated with a significantly lower rate of re-infarction with OR: 0.67, 95% CI: 0.47 – 0.96; P = 0.03,
I2 = 0%.
Conclusion: FFR-guided PCI was not associated with significantly higher adverse clinical outcomes when compared
to angiography-guided PCI. A significantly lower rate of re-infarction associated with FFR-guided PCI could show an
important benefit. However, due to the limited number of patients analyzed, this hypothesis should further be
confirmed in future trials.
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Background
Over the last few years, the total number of patients
undergoing Percutaneous Coronary Intervention (PCI)
with Drug Eluting Stents (DES) has drastically increased.
Because coronary angiography which is normally based
on approximation, often over-estimates or under-
estimates the severity of coronary artery stenosis [1], the
use of Fraction Flow Reserve (FFR)-guided PCI [2] is
gradually showing its clinical importance. FFR is used to
measure the pressure of blood flow in a stenotic artery
through which, a pressure wire is used to calculate/esti-
mate the ratio between the pressure distal to the coron-
ary artery stenosis and pressure in the aorta, under
conditions of maximum myocardial hyperemia. This
method could be beneficial to provide a straightforward,
readily available, quantitative technique to evaluate the
physiologic significance of a coronary artery stenosis [3].
A FFR value of more than 0.80 showed an acceptable or
normal coronary artery whereas a value less than 0.80
predicted stenosis and probably the need for stents im-
plantation [4].
Fraction Flow Reserve Versus Angiography for Multi-
vessel Evaluation (FAME) study, which was the first pub-
lished trial, showed FFR-guided PCI to lower mortality
rate and the rate of re-infarction, at two years, when
compared to the standard angiography-guided PCI [5].
However, newly published trials showed results which
were completely different from the FAME study. For ex-
ample, the Proper Fractional Flow Reserve Criteria for
Intermediate Lesions in the Era of DES (DEFFER-DES)
trial showed no difference in Major Adverse Cardiac
Events (MACEs) which comprised of death, Myocardial
Infarction (MI) and repeated revascularization [6]. Also,
the Double Kissing Crush Versus Provisional Stenting
Technique for Treatment of Coronary Bifurcation Le-
sions VI (DKCRUSH-VI) showed similar clinical out-
comes at one year follow up [7].
Since the benefits associated with FFR-guided PCI
showed controversial issues, we aimed to compare the
adverse clinical outcomes associated with FFR-guided
versus standard angiography-guided PCI using a large
number of randomized patients.
Methods
Data sources and search strategies
PubMed/Medline, EMBASE and the Cochrane library
were searched for studies (English publications) compar-
ing FFR-guided with angiography-guided PCI using the
searched terms ‘fraction flow reserve and percutaneous
coronary intervention’. To further enhance this search,
the words ‘coronary angioplasty’ and the abbreviations
‘FFR and PCI’ were also used. Reference lists of suitable
articles were also carefully checked and reviewed for
relevant studies.
Inclusion and exclusion criteria
Studies were included if:
(a)They were published Randomized Controlled Trials
(RCTs) (an exception was the PLATFORM study
which had several features of a randomized trial
despite of being an observational study).
(b)They compared FFR-guided with angiography-
guided PCI.
(c)They reported adverse outcomes as their clinical
endpoints during any follow up time period after
PCI.
Studies were excluded if:
(a)They were non-RCTs (meta-analyses, observational
studies, case studies and letter to editors) except for
the PLATFORM study.
(b)They did not compare FFR-guided PCI with
angiography-guided PCI.
(c)They did not report adverse outcomes as their
clinical endpoints.
(d)They were associated with the same trial.
(e)They were duplicates.
Outcomes and follow ups




(c)Target Lesion Revascularization (TLR)
(d)Any repeated revascularization including TLR and
Target Vessel Revascularization (TVR)
(e)Major Adverse Cardiac Events (MACEs) which
consisted of death, MI and repeated
revascularization)
Any follow up period after PCI was considered rele-
vant in this study.
Stent thrombosis and TVR could not be analyzed be-
cause they were reported in only one study.
Data extraction and review
First of all two authors (PKB and CMY) independently
assessed the trials which have been included in this ana-
lytic study. Information regarding the type of study re-
ported in each case, the trial name, the clinical outcomes
reported in each trial, and the follow up periods were
carefully extracted by these same two authors. In addition,
data regarding the total number of patients associated
with the FFR-guided and angiography-guided PCI groups
respectively, the patients’ enrollment period, data con-
cerning the baseline features of the patients involved as
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well as the data concerning the adverse clinical events
were systematically extracted. Any disagreement which
occurred was resolved and a final decision was made by
the third author (FH). The six components recommended
by the Cochrane Collaboration were considered when
assessing the risk of bias reported in these trials [8]
(Table 2) whereby a maximum score of 2 points was allo-
cated to each of the six components if a low risk of bias
was observed. A total score of 12 points was allocated de-
pending on the level of bias present. Grades ranging from
A (very low risk of bias) to E (very high risk of bias) were
also allocated with reference to the bias scores obtained.
Statistical analysis
The PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) study guideline was
followed for this systematic review and meta-analysis
[9]. The level of heterogeneity among the subgroups was
assessed using the Cochrane Q-statistic test whereby a P
value of ≤0 · 05 implied that the result was statistically
significant and a P value of > 0.05 implied no statistically
different result obtained. Heterogeneity was also
assessed using the I2-statistic test [10]. If I2 was less than
50%, a fixed effects model was used or else, a random ef-
fects model was relevant. Publication bias was estimated
by the visual method of assessing funnel plots. Odds Ra-
tios (OR) with 95% Confidence Intervals (CIs) were cal-
culated and the analyses were carried out with RevMan
5.3 software. Sensitivity analysis was also performed by
excluding each study one by one, and the outcomes were
analyzed to show if any difference was observed. In this
study, ethical approval was not considered necessary.
Results
Search result
Four hundred and twelve articles were obtained during this
search process. After a careful assessment of the titles and
abstracts, 387 articles were eliminated since they were not
related to the topic of this research. Among the 25 articles
which were screened, a further 9 articles were eliminated
since they were duplicates. Sixteen full-text articles were
assessed for eligibility. Twelve full text articles were elimi-
nated since: two were meta-analyses, six were observational
studies (except the PLATFORM study), and four were asso-
ciated with the same trial. Finally, four articles which satis-
fied the inclusion and exclusion criteria of this study were
included in this meta-analysis. The flow diagram showing
the study selection process has been represented in Fig. 1.
General features of the trials included
A total number of 2138 patients (1080 patients were as-
sociated with FFR-guided PCI whereas 1058 patients
were associated with angiography-guided PCI) were in-
cluded in this analysis. The number of patients extracted
from each study, has been listed in Table 3.
Baseline features of the trials included
Table 4 summarizes the baseline features of the patients
included in this analysis. The mean age of the patients
ranged from 60.1 years to 65.4 years. Trials DIFER-DES,
DKCRUSH-VI and FAME had almost the same number
of male patients in both categories of interventional strat-
egy whereas study PLATFORM had the lowest number of
male patients and patients suffering from hypertension
and diabetes mellitus respectively in both groups (FFR-
guided and angiography guided) with the highest number
of smokers. Although the baseline features of the patients
from one study to the other slightly varied, the difference
was not visible between the groups (FFR guided and angi-
ography guided). Therefore, according to Table 4, there
were no significant differences in baseline features among
patients who were guided by FFR and patients who were
not guided by FFR during PCI.
Analysis of the adverse clinical outcomes associated with
FFR-guided versus angiography guided PCI
The main result of this analysis has been summarized in
Table 5.
Table 1 Outcomes reported
Trials Outcomes reported Follow-up period
DEFER-DES Cardiac death, MI, TLR, all revascularization, MACEs 5 years
DKCRUSH-VI Death, MI, TLR, TVR, MACEs, definite and probable ST 1 year
FAME Death, MI, revascularization 2 years
PLATFORM MACEs, death, MI 3 months
MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, MACEs major adverse cardiac events, ST stent thrombosis
Table 2 Bias risk analysis according to the Cochrane
Collaboration
Trials A B C D E F Total score Bias grade
DEFER-DES 2 2 2 2 1 1 10 B
DKCRUSH-VI 2 2 2 1 2 1 10 B
FAME 2 2 2 2 1 1 10 B
PLATFORM 1 1 2 2 1 1 8 C
A: Sequence generation
B: Allocation sequence concealment
C: Blinding of participants and personnel
D: Blinding of outcome assessment
E: Incomplete outcome data
F: Selective outcome reporting and other potential bias
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Mortality was not significantly different between
FFR-guided and angiography-guided PCI with OR:
0.70, 95% CI: 0.39 – 1.25; P = 0.22, I2 = 0%. Total re-
peated revascularization and TLR were also similarly
manifested with OR: 0.82, 95% CI: 0.60 – 1.13; P =
0.22, I2 = 0% and OR: 0.88, 95% CI: 0.43 – 1.80; P =
0.73, I2 = 0% respectively. In addition, MACEs were
also not significantly higher in the FFR-guided PCI
group with OR: 0.82, 95% CI: 0.64 – 1.06; P = 0.13,
I2 = 0%. However, FFR-guided PCI was associated
with a significantly lower rate of re-infarction with
OR: 0.67, 95% CI: 0.47 – 0.96; P = 0.03, I2 = 0%. The
adverse outcomes reported between FFR-guided ver-
sus angiography-guided PCI have been represented
in Fig. 2.
Sensitivity analysis
An analysis was performed with the exclusion of the trial
DEFER-DES. However, the results were not significantly
different from the main results obtained when all the
four studies were involved. Mortality was not signifi-
cantly different with OR: 0.74, 95% CI: 0.38 – 1.43; P =
0.37, I2 = 0%. Repeated revascularization and MACEs
were also not significantly different with OR: 0.79, 95%
CI: 0.56 – 1.11; P = 0.18, I2 = 0% and OR: 0.82, 95% CI:
0.63 – 1.08; P = 0.16, I2 = 3% respectively. However, MI
approached significant difference with OR: 0.68, 95% CI:
0.47 – 0.99; P = 0.05, I2 = 0%. When the study
DKCRUSH-VI was excluded and an analysis was per-
formed, the result for mortality, repeated revasculariza-
tion and MACEs were still not significant with OR: 0.63,
Fig. 1 Flow diagram representing the study selection
Table 3 General features of the trials included
Features DEFER-DES [6] DKCRUSH-VI [7] FAME [5] PLATFORM [20]
Patients’ enrollment 2006 – 2007 2011 – 2013 2006 – 2007 2013 – 2015
Type of study RCT RCT RCT OS
No of patients in FFR group (n) 114 160 509 297
No of patients in angiography group (n) 115 160 496 287
Total no of patients (n) 229 320 1005 584
RCT randomized controlled trial, OS observational study, FFR fraction flow reserve
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95% CI: 0.34 – 1.18; P = 0.15, I2 = 0%, OR: 0.85, 95% CI:
0.60 – 1.20; P = 0.36, I2 = 0% and OR: 0.78, 95% CI: 0.59
– 1.04; P = 0.09, I2 = 0% respectively. However, MI still
favored the FFR-guided PCI with OR: 0.61, 95% CI: 0.40
– 0.94; P = 0.02, I2 = 0%. Even when the study PLAT-
FORM was excluded, MI significantly favored FFR-
guided PCI with OR: 0.66, 95% CI: 0.46 – 0.94; P = 0.02,
I2 = 0% showing that the sensitivity analyses yielded con-
sistent results. Nevertheless, when an analysis was per-
formed without the study FAME, MI was not
significantly different between these two groups with
OR: 0.81, 95% CI: 0.46 – 1.43; P = 0.47, I2 = 0%.
Based on a visual inspection of the funnel plot obtained,
there were no evidence of publication bias (Fig. 3).
Discussion
In this study, we aimed to compare the adverse clinical
outcomes associated with FFR-guided versus standard
angiography-guided PCI. Results of this study showed
that FFR-guided PCI was not associated with a signifi-
cantly lower rate of mortality or MACEs. The results for
repeated revascularization were also not significantly dif-
ferent. However, FFR-guided PCI was associated with a
significantly lower rate of re-infarction (MI).
Similar to the results of this current study, the
DKCRUSH-VI trial which was a multi-centered random-
ized trial, also showed results which supported this
current analysis [7]. Mortality and MACEs (18.1% in
both groups) were similarly reported at one year follow
up. The DEFER-DES trial also showed no difference in
MACEs at five years follow up [6]. However, this current
analysis showed a different result when MI was analyzed.
In addition, the result for MI also varied during sensitiv-
ity analyses, especially when study FAME [5] was ex-
cluded from the analysis, showing that data from the
study FAME could possibly have had an influence on
the result analyzing MI in this current analysis.
Moreover, the meta-analysis published by Mallidi et al.
which involved prospective cohort studies with a total
number of 525 patients showed no significant difference
in clinical outcomes between these two groups [11].
However, the main focus of that study was on patients
with left main coronary artery disease. In addition, an-
other systematic review and meta-analysis published by
Xiu et al. supported the result of this current analysis
and showed no difference in secondary outcomes includ-
ing death, MACEs and MI reported between the FFR-
guided and angiography guided PCI [12].
However, another meta-analysis, published by Zhang
et al., which also involved a similar number of studies
and patients to that of the above-mentioned study pub-
lished by Xiu et al., showed FFR-guided PCI to be asso-
ciated with a lower rate of MACEs, death, MI and
repeated revascularization with a high level of hetero-
geneity reported among several subgroups analyzed,
compared to the standard angiography-guided PCI [13].
This current study showed results which were com-
pletely different due to the fact that the meta-analysis by
Zhang et al. involved data which were obtained only
from observational studies whereas this current study in-
volved mainly randomized patients.
Nevertheless, the study by Serafino et al. also showed
FFR-guided PCI to be associated with a significantly
lower rate of major adverse cardiovascular and cerebro-
vascular events which deviated completely from the re-
sults of this analysis [14]. However, their study also
involved non-randomized patients who underwent cor-
onary artery bypass surgery.
This current analysis has reported results which were
completely different from the FAME study. Moreover,
results obtained from the sensitivity analyses did not
affect our results at all. Even after excluding the PER-
FORM study which was an observational study, thinking
that it might have affected this current result, no
Table 4 Baseline features of the trials involved
Features DEFER-DES DKCRUSH-VI FAME PLATFORM
FFR/No FFR FFR/No FFR FFR/No FFR FFR/No FFR
Mean age (year) 62.0/63.0 65.2/65.4 64.6/64.2 60.1/60.7
Males (%) 73.0/75.0 75.6/72.5 75.0/73.0 59.7/61.9
Hypertension (%) 64.0/57.0 72.5/68.3 61.0/66.0 56.2/48.7
Dyslipidemia (%) 70.0/68.0 16.9/20.0 72.0/74.0 33.4/31.3
Smoking (%) 26.0/33.0 41.3/40.0 27.0/32.0 54.5/53.6
Diabetes mellitus (%) 26.0/34.0 30.0/26.9 24.0/25.0 10.7/13.7
FFR fraction flow reserve
Table 5 Results of this analysis
Outcomes analyzed OR with 95% CI P value I2 (%)
Mortality 0.70 [0.39 – 1.25] 0.22 0
Myocardial infarction 0.67 [0.47 – 0.96] 0.03 0
Repeated revascularization 0.82 [0.60 – 1.13] 0.22 0
Target lesion revascularization 0.88 [0.43 – 1.80] 0.73 0
Major adverse cardiac events 0.82 [0.64 – 1.06] 0.13 0
OR odds ratios, CI confidence intervals
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Fig. 2 Adverse clinical outcomes associated with FFR-guided versus angiography-guided PCI
Fig. 3 Funnel plot visually representing publication bias
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significant change was observed. Also, including patients
with bifurcation lesions which were thought to affect
our result, did not show any significant change in the
main results when trial DKCRUSH VI (consisting of the
patients with bifurcation lesions) were excluded.
Recent studies have shown an increased application of
FFR in clinical medicine. Several randomized trials and
clinical guidelines in interventional cardiology support
the implementation of FFR in daily clinical practice [15,
16]. FFR-guided interventions are practiced in conditions
such as left intermediate stenosis, also as a guidance
during coronary artery bypass surgery, for the evaluation
of coronary arteries after stents implantation, and in
acute coronary syndrome [3]. Certain centers have even
shifted from ‘operator dependent’ to FFR-dependent’ in
the evaluation of intermediate coronary artery obstruc-
tion in order to improve the prognosis in patients. In
addition, invasive imaging for the assessment of the se-
verity of the left main coronary artery demonstrated ex-
cellent correlation with FFR [17]. Therefore, it is high
time to consider these facts and possibly include FFR
among the decision-making tools in interventional cardi-
ology among certain subgroups of patients.
However, there are conditions which might also re-
strict or limit the use of FFR. Conditions such as chronic
kidney disease (CKD) might impair microcirculation and
increase cardiovascular risk. The FREAK study recently
showed that the index measurement obtained from FFR
and microcirculatory resistance differed significantly be-
tween normal patients and those who suffered from
CKD [18]. The study demonstrated that flow-limiting
FFR was less frequent in patients who had a creatinine
clearance of less or equal to 45 ml per minute. In
addition, Hakeem et al. concluded that strict cautions
should be taken when interpreting FFR values obtained
from patients with stable coronary artery diseases for
clinical decision making in patients with acute coronary
syndrome [19].
Novelty
This study is new in several ways. First of all, it is among
the first meta-analyses involving a large number of ran-
domized patients obtained from recently published trials.
Moreover, no observed heterogeneity was present among
all the subgroups analyzed. Other meta-analyses re-
ported a high level of heterogeneity among several sub-
groups analyzed. This current analysis showed a
heterogeneity I2 with 0% in all the subgroups analyzed.
Even when sensitivity analyses were conducted, almost
all the subgroups showed consistent results. Since the
assessment of heterogeneity is becoming more and more
important in clinical practice, recently Cochrane reviews
strictly started including the value of I2 in order to help
readers assess the consistency of results obtained from
the studies included in meta-analyses so that convincing
and reliable results are produced with evidence. I2 also
does not inherently depend on the number of studies in-
cluded in a meta-analysis which further enhance its use
even with a small sample size. This study might also be
of interest to readers in the way that they can have an
idea to what extent, FFR-guided PCI should be recom-
mended. Moreover, the use of FFR to assess prognosis
could also be taken into consideration.
Limitations
Similar to many other studies, this current study also
has limitations. Due to the limited number of patients,
this analysis might not provide robust results. The
PLATFORM study which was included in this meta-
analysis, was a prospective study that involved non-
randomized patients. However, even if it did not include
randomized patients, this PLATFORM study satisfied
several features that were considered relevant to a ran-
domized controlled trial. This might further contribute
to the limitation in this study.
Conclusions
FFR-guided PCI was not associated with significantly
higher adverse clinical outcomes compared to
angiography-guided PCI. A significantly lower rate of re-
infarction associated with FFR-guided PCI could show
an important benefit. However, since a limited number
of randomized patients were analyzed, this hypothesis
should further be confirmed in future trials.
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